JERSEY CITY, N.J., May 1, 2019 /PRNewswire/ -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company delivering innovative
Ibrexafungerp, the first representative of a novel family of compounds referred to as "fungerps" (antifungal triterpenoids), is being developed for oral and intravenous administration and is in clinical development for the treatment of several serious fungal infections, including VVC, invasive candidiasis, invasive aspergillosis and refractory invasive fungal infections, including Candida auris. Ibrexafungerp is currently in Phase 3 development in VVC.
ACOG, as one of the premier U.S. obstetrics and gynecology clinical and scientific meetings, brings together experts to present their latest findings, guidelines and experiences. Titles and timing of the three ibrexafungerp presentations are as follows:
Title: In Vitro Activity of Ibrexafungerp (SCY-078) Against Candida spp. (including Fluconazole-resistant Isolates) Presenter: Stephen Barat, PhDDate and Time: Friday, May 3, 10:30 AM CDTOral Presentation #: 140P Session: Oral Presentation M
Title: A Phase 2b, Dose-Finding Study Evaluating Oral Ibrexafungerp vs Fluconazole in Vulvovaginal Candidiasis (DOVE)Presenter: David Angulo, MDDate and Time: Saturday, May 4, 11:30 AM CDTPoster Presentation #: 24JSession: ePoster Session J
Title: Ibrexafungerp, a Novel Oral Antifungal, Demonstrates No Reproductive or Developmental Harm in Preclinical Models Presenter: Christina Carruthers, PhDDate and Time: Saturday, May 4, 11:30 AM CDTPoster Presentation #: 25JSession: ePoster Session J
The ACOG 2019 presentations will be available on the SCYNEXIS website following the event.
About SCYNEXISSCYNEXIS, Inc. (NASDAQ: SCYX) is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by developing innovative therapies. The SCYNEXIS team has extensive experience in the life sciences industry, having discovered and developed more than 30 innovative medicines over a broad range of therapeutic areas. SCYNEXIS's lead product candidate, ibrexafungerp (formerly known as SCY-078), is a novel IV/oral antifungal agent in Phase 3 clinical and preclinical development for the treatment of multiple serious and life-threatening invasive fungal infections caused by Candida, Aspergillus and Pneumocystis species. For more information, visit www.scynexis.com.
Forward Looking StatementStatements contained in this press release regarding expected future events or results are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, risks inherent in SCYNEXIS's ability to successfully develop and obtain FDA approval for ibrexafungerp. These and other risks are described more fully in SCYNEXIS's filings with the Securities and Exchange Commission, including without limitation, its most recent Annual Report on Form 10-K under the caption "Risk Factors" and other documents subsequently filed with or furnished to the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. SCYNEXIS undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
CONTACT: Investor RelationsHeather SavelleArgot PartnersTel: firstname.lastname@example.org
Media RelationsGeorge E. MacDougallMacDougallTel: email@example.com
View original content:http://www.prnewswire.com/news-releases/scynexis-to-present-data-at-acog-2019-further-demonstrating-the-favorable-profile-of-ibrexafungerp-for-the-treatment-of-vulvovaginal-candidiasis-vvc-300841608.html
SOURCE SCYNEXIS, Inc.
Subscribe to our Free Newsletters!